SCHEMBL753078

SCHEMBL753078

COc1cccc(OCc2ccccc2)c1C1NC(=O)C(C)(C)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.44
BRD4 O60885 2/20 0.43
CREBBP Q92793 2/20 0.43
CTSV O60911 2/20 0.41
CTSL P07711 2/20 0.41
MAPT P10636 2/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
HTR1A P08908 3/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
RXRA P19793 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
ATM Q13315 1/20 0.40
PDE4A P27815 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30416387 0.68 HTR1A (0.74) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL791853 0.68 HTR1A (0.74) MAPTMAPK1TDP1L3MBTL1MRGPRX4
Ammonia Solution, Strong SCHEMBL2063054 0.66 HTR1A (0.72) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL6312645 0.65 HTR1A (0.63) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL18623128 0.65 HTR1A (0.68) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL1253794 0.65 MAPT (0.85) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL21300617 0.65 BCHE (0.67) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL17912878 0.65 MAPT (0.66) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL4599397 0.65 RXRA (0.60) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL5733348 0.64 SIRT2 (0.46) SIRT2BRD4CREBBPMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430004-B1 NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-07-17 EP disclosed
US-8329706-B2 Oxazolidinone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-12-11 US disclosed
US-20120101111-A1 NOVEL OXAZOLIDINONE DERIVIATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2012-04-26 US disclosed
EP-2430004-A2 NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-03-21 EP disclosed
WO-2010131192-A2 NOVEL OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101111-A1 NOVEL OXAZOLIDINONE DERIVIATIVES HCRTR2, HCRTR1, NPY4R SIRT2 607/4885BRD4 977/4885CREBBP 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.